Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.

Literature DB >> 27003694

Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.

Abstract

Tasimelteon (Hetlioz(®)) is a dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) (free-running disorder). In two randomized, double-masked, multicentre, phase III trials, totally blind individuals with Non-24 who received oral tasimelteon 20 mg once nightly were significantly more likely than those receiving placebo to entrain the circadian pacemaker (the SET trial) and maintain entrainment (the RESET trial). Sleep/wake parameters and functioning were also improved with tasimelteon. Oral tasimelteon was generally well tolerated in totally blind patients with Non-24. In conclusion, tasimelteon is a useful drug for the treatment of Non-24 in totally blind individuals.

Entities: Disease Species

Mesh：

Substances：

Year: 2016 PMID： 27003694 DOI： 10.1007/s40263-016-0330-y

Source DB: PubMed Journal: CNS Drugs ISSN： 1172-7047 Impact factor: 5.749

24 in total

1. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects.

Authors: Lisa M Hack; Steven W Lockley; Josephine Arendt; Debra J Skene
Journal: J Biol Rhythms Date: 2003-10 Impact factor: 3.182

2. Entraining the free-running circadian clocks of blind people.

Authors: Charmane Eastman
Journal: Lancet Date: 2015-10-31 Impact factor: 79.321

3. Tasimelteon: a selective and unique receptor binding profile.

Authors: Christian Lavedan; Mark Forsberg; Anthony J Gentile
Journal: Neuropharmacology Date: 2014-12-19 Impact factor: 5.250

Review 4. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors: Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal: Annu Rev Pharmacol Toxicol Date: 2015-10-23 Impact factor: 13.820

5. Stability, precision, and near-24-hour period of the human circadian pacemaker.

Authors: C A Czeisler; J F Duffy; T L Shanahan; E N Brown; J F Mitchell; D W Rimmer; J M Ronda; E J Silva; J S Allan; J S Emens; D J Dijk; R E Kronauer
Journal: Science Date: 1999-06-25 Impact factor: 47.728

6. Blacks (African Americans) have shorter free-running circadian periods than whites (Caucasian Americans).

Authors: Charmane I Eastman; Thomas A Molina; Marissa E Dziepak; Mark R Smith
Journal: Chronobiol Int Date: 2012-08-16 Impact factor: 2.877

Review 7. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.

Authors: Stephen M Stahl
Journal: CNS Spectr Date: 2014-12 Impact factor: 3.790

8. Melatonin administration can entrain the free-running circadian system of blind subjects.

Authors: S W Lockley; D J Skene; K James; K Thapan; J Wright; J Arendt
Journal: J Endocrinol Date: 2000-01 Impact factor: 4.286

9. Human tau in an ultradian light-dark cycle.

Authors: Helen J Burgess; Charmane I Eastman
Journal: J Biol Rhythms Date: 2008-08 Impact factor: 3.182

Review 10. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review.

Authors: Robert L Sack; Dennis Auckley; R Robert Auger; Mary A Carskadon; Kenneth P Wright; Michael V Vitiello; Irina V Zhdanova
Journal: Sleep Date: 2007-11 Impact factor: 5.849

3 in total